
Sign up to save your podcasts
Or
At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.
3.7
33 ratings
At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.
785 Listeners
325 Listeners
22,074 Listeners
496 Listeners
135 Listeners
58 Listeners
183 Listeners
2 Listeners
3,685 Listeners
9 Listeners
56 Listeners
0 Listeners
1,619 Listeners
0 Listeners
2 Listeners